Camzyos is currently the only FDA-approved treatment for HCM and at launch was tipped as a future blockbuster, although its growth has been pegged back by a somewhat onerous risk evaluation and ...

Camzyos (mavacamten), a first-in-class heart disease drug, was approved by the FDA on April 28, 2022 to treat symptomatic obstructive hypertrophic cardiomyopathy (HCM), a genetic condition that causes ...

Bristol-Myers Squibb is going after a second indication for its first-to-market cardiac myosin inhibitor Camzyos, a drug tipped to be a future blockbuster and the top prospect in the company's ...